An observational study in Hip Arthritis, Hip Disease and Hip Fractures, sponsored by Zimmer Biomet. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Zimmer Biomet · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Hip Fractures by Zimmer Biomet — 5 open to participants now, 8 under way, none of them phase 3. Hip Fractures · Zimmer Biomet.
Among the 16 studies in Hip Fractures by Zimmer Biomet, this one is the 7th largest by planned enrollment of the 11 observational ones that give a count, is one of 2 that started in 2026, is one of 11 observational ones, and was the 12th registered.
843 studies on the registry are indexed under Hip Fractures; 166 are open to participants now.
Browse Hip Fractures studies →5 of the 16 studies in Hip Fractures by Zimmer Biomet are open now, in 4 countries. Recruiting first, the newest first:
Zimmer Biomet · Sites in United States
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18+
Zimmer Biomet · Sites in United States
Ages 18–80
Zimmer Biomet · Sites in United States, Belgium, Italy and 1 more country
Ages 18–80
By country, each count listing its studies:
Of the 104 Hip Fractures studies recruiting now, 82 (79%) set no upper age limit and 6 (6%) stop at 75 or younger; 12 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 116 is below the median of 149 across 280 observational studies indexed under Hip Fractures.
Median enrollment 240 across the 5 interventional studies, 149 across the 11 observational. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
Zimmer Biomet is the lead sponsor of 275 studies on the registry; 28 are open to participants now.
Of its 22 completed or terminated interventional studies of FDA-regulated products, 19 (86%) have results posted.
1 of the studies in Hip Fractures by Zimmer Biomet that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05199870Zimmer BiometMDR - PMCF Study for RingLoc Bipolar Acetabular Cup and Endo II Femoral Heads | 2027-03 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Hip Fractures by Zimmer Biomet, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and the Endo II Femoral Head when used for hip hemiarthroplasty (implants and instrumentation).
The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the RingLoc Bipolar Acetabular Cup and the Endo II Femoral Head when used for hip hemiarthroplasty (implants and instrumentation).
The primary objective of this study is the assessment of safety by analyzing implant survivorship at the longest follow-up timepoint available, greater than or equal to eight years post-implantation. This will be established by recording the incidence and frequency of revisions, complications, and adverse events. Relationship of the events to implant, instrumentation and/or procedure should be specified.
The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcomes measures (PROMs).
A consecutive series of patients implanted with the RingLoc Bipolar acetabular cup or the Endo II Femoral Head.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient must have undergone hip hemiarthroplasty surgery with the RingLoc Bipolar Acetabular Cup or Endo II Femoral Head for a cleared indication, greater than or equal to eight years previous to the date of study consent. Cleared indications for the RingLoc Bipolar and Endo II Heads include the following:
Exclusion Criteria:
Patients that have been implanted with the RingLoc Bipolar acetabular cup to repair hip malfunction/disease/injury.
Device: RingLoc Bipolar Acetabular Cup
Subjects who were implanted with the Endo II Femoral head during hemiarthroplasty
Device: Endo II Femoral Head
Patients that have been implanted with a RingLoc Bipolar acetabular cup.
Subjects that have been implanted with an Endo II Femoral Head
Device safety assessed through the frequency and incidence of revisions, complications, and Adverse Events.
The primary objective of this study is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications, and Adverse Events. Relation of the events to either implant or instrumentation will be specified.
Time frame: Greater than or equal to 8 years.
Device Performance and Benefits evaluated through the Oxford Hip Score and Patient Assessment.
The OHS is a patient-completed, 12-question evaluation. Each item is scored from 1 to 5, with 1 representing best outcome/least symptoms and 5 representing worst outcome/most symptoms. The Patient Assessment is patient completed and a 4-question evaluation.
Time frame: Greater than or equal to 8 years.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 124 observational studies under Hip Fractures, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 83. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.